Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

EST Altimmune (ALT) files $400M mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

William Blair analyst Andy Hsieh initiated coverage of Altimmune (ALT) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, MarketBeat reports. One equities research ...

Altimmune (NASDAQ:ALT – Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th.Analysts expect the company to announce earnings ...

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

Good day, ladies and gentlemen, and welcome to Altimmune fourth quarter and full year 2024 financial results conference call. As a reminder, this call is being recorded. (Operator Instructions) I ...